Steven Mitchell
Psychiatry · Seattle, WANPI 1821265091
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AbbVie at 54.5% of the total. Reporting peaked in 2019 at $2,731 and has fallen 94.4% since, to $154 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $43.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$448
- Jazz Pharmaceuticals Inc.$345
- Otsuka America Pharmaceutical, Inc.$341
- Sunovion Pharmaceuticals Inc.$229
- Ironshore Pharmaceuticals Inc.$228
- plus $2K from 19 others
What the payments were for
- Consulting fees$1753%
- Speaking & faculty fees$3,00044%
- Travel & lodging$200%
- Food & beverage$3,59052%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $3,724 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $448 |
| Jazz Pharmaceuticals Inc. | 3 | $345 |
| Otsuka America Pharmaceutical, Inc. | 8 | $341 |
| Sunovion Pharmaceuticals Inc. | 10 | $229 |
| Ironshore Pharmaceuticals Inc. | 5 | $228 |
| Corium, LLC | 9 | $201 |
| Johnson & Johnson | 5 | $188 |
| Bayer | 8 | $186 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $175 |
| Gilead | 7 | $138 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $115 |
| Bausch Health US, LLC | 4 | $80 |
| Genentech USA, Inc. | 4 | $75 |
| Tris Pharma Inc | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $45 |
| Avion Pharmaceuticals | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Alkermes, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Agile Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$3,000
- SUNOSI$245
- ABILIFY MYCITE$175
- Jornay PM 20mg capsules (Bottle of 100)$154
- REXULTI$128
- SPRAVATO$106
How this compares
$6,839 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 11 | $2,997 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 41 | $1,756 |
| Mirtazapine | 46 | $836 |
| Buspirone Hcl | 14 | $680 |
| Bupropion XlBupropion Hcl | 13 | $644 |
| Lamotrigine | 28 | $632 |
| Clonazepam | 39 | $472 |
| Methylphenidate Hcl | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Seattle
- Chester RobachinskiSeattle$1.1M
- Pablo ProanoSeattle$112K
- Jesse McClellandSeattle$39K
- Lina FineSeattle$30K
- Jonathan BuchholzSeattle$7K
- Randall EspinozaSeattle$6K
- John KernSeattle$6K
- James BowenSeattle$4K
- Gerard ZanolliSeattle$3K
- Shahm MartiniSeattle$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.